Optimal control analysis of combined anti-angiogenic and tumor immunotherapy
The author considers a mathematical model of immunotherapy and anti-angiogenesis inhibitor therapy for cancer patients over a fixed time horizon. Disease dynamics are captured by a system of ODEs developed in [1], describing dynamics among host cells, cancer cells, endothelial cells, effector cells,...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Ptolemy Scientific Research Press
2019-11-01
|
Series: | Open Journal of Mathematical Sciences |
Subjects: | |
Online Access: | https://pisrt.org/psr-press/journals/oms-vol-3-2019/optimal-control-analysis-of-combined-anti-angiogenic-and-tumor-immunotherapy/ |
id |
doaj-4750eb1547024d0a9caf13e0f9f28a80 |
---|---|
record_format |
Article |
spelling |
doaj-4750eb1547024d0a9caf13e0f9f28a802020-11-25T02:23:40ZengPtolemy Scientific Research PressOpen Journal of Mathematical Sciences2616-49062523-02122019-11-013134935710.30538/oms2019.0078Optimal control analysis of combined anti-angiogenic and tumor immunotherapyAnuraag Bukkuri0Department of Mathematics, University of Minnesota, Minneapolis, MN 55455, USA.The author considers a mathematical model of immunotherapy and anti-angiogenesis inhibitor therapy for cancer patients over a fixed time horizon. Disease dynamics are captured by a system of ODEs developed in [1], describing dynamics among host cells, cancer cells, endothelial cells, effector cells, and anti-angiogenesis. Existence, uniqueness, and characterization of optimal treatment profiles that minimize the tumor and drug usage, while maintaining healthy levels of effector and host cells are determined. A theoretical analysis is performed to characterize the optimal control. Numerical simulations are performed to illustrate optimal control profiles for a variety of different patients, each leading to different treatment protocols.https://pisrt.org/psr-press/journals/oms-vol-3-2019/optimal-control-analysis-of-combined-anti-angiogenic-and-tumor-immunotherapy/optimal controlimmunotherapyanti-angiogenesis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anuraag Bukkuri |
spellingShingle |
Anuraag Bukkuri Optimal control analysis of combined anti-angiogenic and tumor immunotherapy Open Journal of Mathematical Sciences optimal control immunotherapy anti-angiogenesis |
author_facet |
Anuraag Bukkuri |
author_sort |
Anuraag Bukkuri |
title |
Optimal control analysis of combined anti-angiogenic and tumor immunotherapy |
title_short |
Optimal control analysis of combined anti-angiogenic and tumor immunotherapy |
title_full |
Optimal control analysis of combined anti-angiogenic and tumor immunotherapy |
title_fullStr |
Optimal control analysis of combined anti-angiogenic and tumor immunotherapy |
title_full_unstemmed |
Optimal control analysis of combined anti-angiogenic and tumor immunotherapy |
title_sort |
optimal control analysis of combined anti-angiogenic and tumor immunotherapy |
publisher |
Ptolemy Scientific Research Press |
series |
Open Journal of Mathematical Sciences |
issn |
2616-4906 2523-0212 |
publishDate |
2019-11-01 |
description |
The author considers a mathematical model of immunotherapy and anti-angiogenesis inhibitor therapy for cancer patients over a fixed time horizon. Disease dynamics are captured by a system of ODEs developed in [1], describing dynamics among host cells, cancer cells, endothelial cells, effector cells, and anti-angiogenesis. Existence, uniqueness, and characterization of optimal treatment profiles that minimize the tumor and drug usage, while maintaining healthy levels of effector and host cells are determined. A theoretical analysis is performed to characterize the optimal control. Numerical simulations are performed to illustrate optimal control profiles for a variety of different patients, each leading to different treatment protocols. |
topic |
optimal control immunotherapy anti-angiogenesis |
url |
https://pisrt.org/psr-press/journals/oms-vol-3-2019/optimal-control-analysis-of-combined-anti-angiogenic-and-tumor-immunotherapy/ |
work_keys_str_mv |
AT anuraagbukkuri optimalcontrolanalysisofcombinedantiangiogenicandtumorimmunotherapy |
_version_ |
1724857989132713984 |